133 related articles for article (PubMed ID: 36842760)
1. Clinical and immunological features of patients with cancer-associated systemic sclerosis: An observational study.
Lopez L; Barnetche T; Galli G; Seneschal J; Blanchard E; Shipley E; Pellegrin JL; Lazaro E; Constans J; Duffau P; Schaeverbeke T; Richez C; Kostine M; Truchetet ME
Joint Bone Spine; 2023 May; 90(3):105555. PubMed ID: 36842760
[TBL] [Abstract][Full Text] [Related]
2. Clinical Features and Risk Factors of Rapidly Progressive Systemic Sclerosis in a Single Center in China: Anti-RNA Polymerase III Antibodies as a Predictor.
Yu Q; Zhang J; Fan L; Yu T; Liu B; Ding J
Discov Med; 2023 Apr; 35(175):193-200. PubMed ID: 37105929
[TBL] [Abstract][Full Text] [Related]
3. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
[TBL] [Abstract][Full Text] [Related]
4. Systemic Sclerosis-Specific Antibodies: Novel and Classical Biomarkers.
Cavazzana I; Vojinovic T; Airo' P; Fredi M; Ceribelli A; Pedretti E; Lazzaroni MG; Garrafa E; Franceschini F
Clin Rev Allergy Immunol; 2023 Jun; 64(3):412-430. PubMed ID: 35716254
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and risk factors of systemic sclerosis-associated interstitial lung disease in East Asia: A systematic review and meta-analysis.
Qiu M; Nian X; Pang L; Yu P; Zou S
Int J Rheum Dis; 2021 Dec; 24(12):1449-1459. PubMed ID: 34418313
[TBL] [Abstract][Full Text] [Related]
6. Incidence, Risk Factors, and Outcomes of Cancer in Systemic Sclerosis.
Morrisroe K; Hansen D; Huq M; Stevens W; Sahhar J; Ngian GS; Ferdowsi N; Hill C; Roddy J; Walker J; Proudman S; Nikpour M
Arthritis Care Res (Hoboken); 2020 Nov; 72(11):1625-1635. PubMed ID: 31539207
[TBL] [Abstract][Full Text] [Related]
7. Systemic Sclerosis Association with Malignancy.
Lepri G; Catalano M; Bellando-Randone S; Pillozzi S; Giommoni E; Giorgione R; Botteri C; Matucci-Cerinic M; Antonuzzo L; Guiducci S
Clin Rev Allergy Immunol; 2022 Dec; 63(3):398-416. PubMed ID: 36121543
[TBL] [Abstract][Full Text] [Related]
8. Absence of interstitial lung disease at initial visit may predict a favorable outcome for Japanese patients with systemic sclerosis with anti-topoisomerase I antibody.
Hamaguchi Y; Yoshimura Y; Horii M; Fushida N; Kitano T; Sawada K; Oishi K; Maeda S; Watanabe S; Matsushita T
J Dermatol; 2024 Jan; 51(1):62-69. PubMed ID: 37864453
[TBL] [Abstract][Full Text] [Related]
9. [Cancers in systemic sclerosis : risk factors, impact on survival and literature review].
Catano J; Guedon A; Riviere S; Carrat F; Mahevas T; Fain O; Mekinian A
Rev Med Interne; 2019 Oct; 40(10):637-644. PubMed ID: 31255252
[TBL] [Abstract][Full Text] [Related]
10. [Characteristics of patients with systemic sclerosis who develop interstitial lung disease].
Fajardo-Hermosillo LD; Ocampo-Torres MC; Rodríguez-Silverio J
Rev Med Inst Mex Seguro Soc; 2023 Oct; 61(Suppl 3):S363-S371. PubMed ID: 37934671
[TBL] [Abstract][Full Text] [Related]
11. Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma.
Moinzadeh P; Fonseca C; Hellmich M; Shah AA; Chighizola C; Denton CP; Ong VH
Arthritis Res Ther; 2014 Feb; 16(1):R53. PubMed ID: 24524733
[TBL] [Abstract][Full Text] [Related]
12. Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort.
Nikpour M; Hissaria P; Byron J; Sahhar J; Micallef M; Paspaliaris W; Roddy J; Nash P; Sturgess A; Proudman S; Stevens W
Arthritis Res Ther; 2011; 13(6):R211. PubMed ID: 22189167
[TBL] [Abstract][Full Text] [Related]
13. Registry of the Spanish network for systemic sclerosis: clinical pattern according to cutaneous subsets and immunological status.
Simeón-Aznar CP; Fonollosa-Plá V; Tolosa-Vilella C; Espinosa-Garriga G; Ramos-Casals M; Campillo-Grau M; García-Hernández FJ; Castillo-Palma MJ; Sánchez-Román J; Callejas-Rubio JL; Ortego-Centeno N; Egurbide-Arberas MV; Trapiellla-Martínez L; Gallego-Villalobos M; Sáez-Comet L; Velilla-Marco J; Camps-García MT; de Ramón-Garrido E; Esteban Marcos EM; Pallarés-Ferreres L; Hidalgo-Tenorio C; Sabio-Sánchez JM; Gómez-de la Torre R; Salvador-Cervello G; Rios-Blanco JJ; Gil-Aguado A; Vilardell-Tarrés M
Semin Arthritis Rheum; 2012 Jun; 41(6):789-800. PubMed ID: 22169458
[TBL] [Abstract][Full Text] [Related]
14. Influence of antibody profile in clinical features and prognosis in a cohort of Spanish patients with systemic sclerosis.
Iniesta Arandia N; Simeón-Aznar CP; Guillén Del Castillo A; Colunga Argüelles D; Rubio-Rivas M; Trapiella Martínez L; García Hernández FJ; Sáez Comet L; Egurbide Arberas MV; Ortego-Centeno N; Freire M; Marí Alfonso B; Vargas Hitos JA; Ríos Blanco JJ; Todolí Parra JA; Rodríguez-Carballeira M; Marín Ballvé A; Chamorro Fernández AJ; Pla Salas X; Madroñero Vuelta AB; Ruiz Muñoz M; Fonollosa Pla V; Espinosa G;
Clin Exp Rheumatol; 2017; 35 Suppl 106(4):98-105. PubMed ID: 28980912
[TBL] [Abstract][Full Text] [Related]
15. Incidence Rate and Prevalence of Systemic Sclerosis and Systemic Sclerosis-Associated Interstitial Lung Disease in Japan: Analysis Using Japanese Claims Databases.
Kuwana M; Saito A; Sakamoto W; Raabe C; Saito K
Adv Ther; 2022 May; 39(5):2222-2235. PubMed ID: 35316503
[TBL] [Abstract][Full Text] [Related]
16. Clinical algorithms for the diagnosis and prognosis of interstitial lung disease in systemic sclerosis.
Hax V; Bredemeier M; Didonet Moro AL; Pavan TR; Vieira MV; Pitrez EH; da Silva Chakr RM; Xavier RM
Semin Arthritis Rheum; 2017 Oct; 47(2):228-234. PubMed ID: 28454677
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of anti-synthetase antibodies among systemic sclerosis patients.
Garra W; Levy Y
Eur J Intern Med; 2023 Nov; 117():98-102. PubMed ID: 37453844
[TBL] [Abstract][Full Text] [Related]
18. Anti-Ro52 positivity is associated with progressive interstitial lung disease in systemic sclerosis-an exploratory study.
Hamberg V; Sohrabian A; Volkmann ER; Wildt M; Löfdahl A; Wuttge DM; Hesselstrand R; Dellgren G; Westergren-Thorsson G; Rönnelid J; Andréasson K
Arthritis Res Ther; 2023 Sep; 25(1):162. PubMed ID: 37667402
[TBL] [Abstract][Full Text] [Related]
19. Autoantibodies associated with systemic sclerosis in three autoimmune diseases imprinted by type I interferon gene dysregulation: a comparison across SLE, primary Sjögren's syndrome and systemic sclerosis.
Andraos R; Ahmad A; Eriksson P; Dahlström Ö; Wirestam L; Dahle C; Hesselstrand R; Bengtsson AA; Jönsen A; Andréasson K; Sjöwall C
Lupus Sci Med; 2022 Dec; 9(1):. PubMed ID: 36581379
[TBL] [Abstract][Full Text] [Related]
20. The association between air pollution and the severity at diagnosis and progression of systemic sclerosis-associated interstitial lung disease: results from the retrospective ScleroPol study.
Roeser A; Sese L; Chassagnon G; Chaigne B; Dunogue B; Tran Ba S; Jebri S; Brillet PY; Revel MP; Aubourg F; Dhote R; Caux F; Annesi-Maesano I; Mouthon L; Nunes H; Uzunhan Y
Respir Res; 2023 Jun; 24(1):151. PubMed ID: 37291562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
